Abstract:Abstract Backgrounds Liver hepatocellular carcinoma (HCC) is one of the most malignant tumors, of which prognosis is unsatisfactory in most cases and metastatic of HCC often results in poor prognosis. In this study, we aimed to construct a metastasis- related mRNAs prognostic model to increase the accuracy of prediction of HCC prognosis. Methods Three hundred seventy-four HCC samples and 50 normal samples were downloaded from The Cancer Genome Atlas (TCGA) database, involving transcriptomic and clinical data. Metastatic-related genes were acquired from HCMBD website at the same time. Two hundred thirty-three samples were randomly divided into train dataset and test dataset with a proportion of 1:1 by using caret package in R. Kaplan-Meier method and univariate Cox regression analysis and lasso regression analysis were performed to obtain metastasis-related mRNAs which played significant roles in prognosis. Then, using multivariate Cox regression analysis, a prognostic prediction model was established. Transcriptome and clinical data were combined to construct a prognostic model and a nomogram for OS evaluation. Functional enrichment in high- and low-risk groups were also analyzed by GSEA. An entire set based on The International Cancer Genome Consortium(ICGC) database was also applied to verify the model. The expression levels of SLC2A1, CDCA8, ATG10 and HOXD9 are higher in tumor samples and lower in normal tissue samples. The expression of TPM1 in clinical sample tissues is just the opposite. Results One thousand eight hundred ninety-five metastasis-related mRNAs were screened and 6 mRNAs were associated with prognosis. The overall survival (OS)-related prognostic model based on 5 MRGs (TPM1,SLC2A1, CDCA8, ATG10 and HOXD9) was significantly stratified HCC patients into high- and low-risk groups. The AUC values of the 5-gene prognostic signature at 1 year, 2 years, and 3 years were 0.786,0.786 and 0.777. A risk score based on the signature was a significantly independent prognostic factor (HR = 1.434; 95%CI = 1.275–1.612; P < 0.001) for HCC patients. A nomogram which incorporated the 5-gene signature and clinical features was also built for prognostic prediction. GSEA results that low- and high-risk group had an obviously difference in part of pathways. The value of this model was validated in test dataset and ICGC database. Conclusion Metastasis-related mRNAs prognostic model was verified that it had a predictable value on the prognosis of HCC, which could be helpful for gene targeted therapy.

Supplementary Figures 1-3, Table 1 from A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients

Identification of a Novel Signature Based on Macrophage-Related Marker Genes to Predict Prognosis and Immunotherapeutic Effects in Hepatocellular Carcinoma.

Supplementary Figures from the Prediction of Clinical Outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature

Validation and Clinical Utility of A Human Hepatocellular Carcinoma Metastasis Signature As Prognostic Classifier

A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules

Identification and Validation of a Potent Multi-Mrna Signature for the Prediction of Early Relapse in Hepatocellular Carcinoma.

Novel Gene Signatures Promote Epithelial-Mesenchymal Transition (EMT) in Glucose Deprivation-Based Microenvironment to Predict Recurrence‐Free Survival in Hepatocellular Carcinoma

Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases

Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma

Identification and Validation of Novel Metastasis-Related Signatures of Clear Cell Renal Cell Carcinoma Using Gene Expression Databases.

Prediction of Prognosis in Hepatocellular Carcinoma Based on A Gene Signature from Highly Tumorigenic Liver Cancer Cells

Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma

Comprehensive Molecular Analyses of a Six-Gene Signature for Predicting Late Recurrence of Hepatocellular Carcinoma

Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-included Resected Hepatocellular Carcinoma Patients

A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients

Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma

A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases

Table S4 from Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma

An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma

Abstract A25: Array-based Comparative Genomic Hybridization of Hepatocellular Carcinoma Reveals a Unique Genomic Aberration Pattern in Tumors with Poor Prognosis

Development And Validation Of A Metabolic Gene-Based Prognostic Signature For Hepatocellular Carcinoma